Main distributor to Brazil and Latin America for analytical reference substances  |  Welcome! Olá! Hola! Español  |  +1.919.484.7555
You are here: Home /Healthcare, Science /Sanofi and Lexicon to develop diabetes drug sotagliflozin – Pharmaceutical Technology

Sanofi and Lexicon to develop diabetes drug sotagliflozin – Pharmaceutical Technology

by JMC on November 11, 2015

French drugmaker Sanofi has entered a collaboration and licence agreement with US-based Lexicon Pharmaceuticals to develop and commercialise sotagliflozin, which could be a potential treatment option for people with diabetes.Sotagliflozin is an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2).As part of the deal, Lexicon will receive an upfront payment of $300m and is eligible to receive development, regulatory and sales milestone payments of up to $1.4bn.In addition, Lexicon is entitled to tiered, escalating double digit percentage royalties of net sales of sotagliflozin.

Source: Sanofi and Lexicon to develop diabetes drug sotagliflozin – Pharmaceutical Technology

Previous post:

Next post: